High Expression of ACE2 and TMPRSS2 at the Resection Margin Makes Lung Cancer Survivors Susceptible to SARS-CoV-2 with Unfavorable Prognosis

Qianqian Wang
   The First Affiliated Hospital of Nanjing Medical University

Liangyu Li
   Nanjing Medical University

Tianyu Qu
   The First Affiliated Hospital of Nanjing Medical University

Lingxiang Wu
   Nanjing Medical University

Kening Li
   Nanjing Medical University

Ziyu Wang
   Nanjing Medical University

Mengyan Zhu
   Nanjing Medical University

Bin Huang
   Nanjing Medical University

Wei Wu
   Nanjing Medical University

Min Wu
   Nanjing Medical University

Rong Ding
   Nanjing Medical University

Zhihong Zhang
   The First Affiliated Hospital of Nanjing Medical University

Qianghu Wang ( wangqh@njmu.edu.cn )
   Nanjing Medical University

Xinyi Xia
   Jinling Hospital and Nanjing University School of Medicine and Southern Medical University and Wuhan Huoshenshan Hospital

Zhi Zhang
Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University
Affiliated Cancer Hospital

Renhua Guo
First Affiliated Hospital of Nanjing Medical University

Short Report

Keywords: COVID-19, Lung cancer, ACE2

DOI: https://doi.org/10.21203/rs.3.rs-100141/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide. Systematic analysis of lung cancer survivors at molecular and clinical levels is warranted to understand the disease course and clinical characteristics. We performed a retrospective study of 65 patients with COVID-19 from Wuhan Huoshenshan Hospital, of which 13 patients were diagnosed with lung cancer. During treatment, lung cancer survivors infected with severe acute respiratory syndrome coronavirus 2 had a shorter median time from symptom onset to hospitalization ($P=0.016$) and longer clinical symptom remission time ($P=0.020$) than non-cancer individuals. No differences were observed among indicators such as time from symptom onset to hospitalization and symptom remission time between long-term and short-term survivors. The expression of $ACE2$ ($P=0.013$) and $TMPRSS2$ ($P<0.001$) was elevated in lung cancer survivors as compared with that in non-cancer individuals.

Results

Demographic and clinical characteristics of patients

Records of 3,057 patients with confirmed Coronavirus disease 2019 (COVID-19) infection were collected from the Wuhan Huoshenshan Hospital between February 4 and April 11, 2020. Thirteen patients (0.43%) who suffered from lung cancer and 52 matched patients were enrolled. The demographic and clinical features of these patients are shown in Table 1. The median (IQR) age of lung cancer patients was 65 (63-72) years, and 10 (76.9%) of them were men. The most common comorbidities were hypertension and diabetes observed in 30.8% patients. No significant differences were found in age, sex, and main symptoms and signs between the case and control groups. Further, the most prevalent symptom among the 65 enrolled patients was fever ($n=50, 76.9$%), followed by cough ($n=41, 63.1$%), fatigue ($n=30, 46.2$%), and shortness of breath ($n=26, 40.0$%).

Lung cancer patients were more likely to have dyspnea (15.4% vs. 1.9%; $P=0.040$) than the other groups (Table S1). Five of these patients were long-term survivors, and none of them was diagnosed with stage IV cancer. All patients received at least one kind of antitumor treatment, including surgery ($n=7, 53.8$%), chemotherapy ($n=6, 46.2$%), epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy ($n=2, 15.4$%), anti-angiogenesis therapy ($n=1, 7.7$%), and radiotherapy ($n=2, 15.4$%), while none of the long-term survivors received treatment within past 3 months. The percentage of long-term survivors who underwent surgery was four-fold higher than that of short-term survivors (100.0% vs. 25.0%, $P=0.011$). No difference was observed in comorbidities and symptoms between long- and short-term survivors (Table S1).

Clinical outcomes
During treatment, development of severe infection was more common among lung cancer patients (Wilcoxon's rank-sum test, \( P=0.064 \)) (Table 2). The duration of symptoms before hospital admission in lung cancer patients was 10.5 (10.0-17.5) days, which was significantly shorter than that observed in other patients (30.0 [14.0-35.0]; Wilcoxon's rank-sum test, \( P=0.016 \)) (Table 2). Moreover, the average time to clinical improvement in lung cancer patients was 12 (11.0-18.0) days, which was 4 days longer than that observed in non-cancer patients (5.8-14.0) (Wilcoxon's rank-sum test, \( P=0.020 \)) (Table 2). The mortality (7.7%, 1/13) observed in our study was higher than that reported in the general population (2.3%) and lower than that (18.18%; 4/22) noted in a multicenter study\(^1\,\,^2\). There were no differences among indicators such as time from symptoms to hospitalization and symptom remission time between long-term and short-term survivors (Table S2). These findings suggested that lung cancer patients represent a highly vulnerable group to the current COVID-19 outbreak.

**ACE2 and TMPRSS2 are overexpressed at resection margins of lung cancer patients**

Several studies have shown that coronaviruses enter cells via binding of the viral spike (S) proteins to cellular receptors ACE2 and following S protein priming by host cell proteases. TMPRSS2 as a transmembrane protease can induce the virus-plasma membrane fusion\(^3\,\,^4\). Hoffmann and coworkers recently demonstrated that Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming\(^5\,\,^6\). ACE2 is broadly expressed in epithelial cells\(^7\). We then evaluated if resection margins of lung cancer harbor more epithelial cells. We collected three resection margin tissues from lung cancer and three other non-cancerous lung tissues (Table S3). We performed IHC to investigate the population of epithelial cells among the two groups, and found that the percentage of the stained area was much higher in the resection margin tissues than in the non-cancerous tissues (Figure 1A, B).

We analyzed single-cell sequencing data from the existing research\(^8\) and found that the epithelial cells at the resection margin of lung cancer were more likely to highly activate the genes related to lung cancer, such as KRAS, MET, and EGFR (Figure 1C, D). The genomic instability of these cells inferred by inferCNV in the resection margin was much higher than that in the normal tissues (Figure 1E), and these cells had stronger capability for invasion and infiltration (Figure 1F). These findings suggested that the cells at the margin of resection were more likely to be a sort of tumor-like cells.

The proportion of epithelial cells expressing ACE2 and TMPRSS2 was higher at the resection margin of lung cancers than in normal tissues (Figure 1G), suggesting that the resection margins of lung cancer tissues were still more susceptible to COVID-19 infection. We also analyzed the expression of ACE2 in resection margin tissues of lung cancer survivors and normal lung tissues from general individuals using The Cancer Genome Atlas (n=110) and GTEx (n=288) databases and found that the mRNA expression of ACE2 was higher in lung cancer patients than in general individuals (Wilcoxon's rank-sum test, \( P=0.013 \)) (Figure 1H). The expression of TMPRSS2, the co-factor of ACE2, was also significantly higher in lung cancer patients than in the general population (Wilcoxon's rank-sum test, \( P<0.001 \)) (Figure 1H), suggesting that patients with lung cancer were more likely to be susceptible to COVID-19.
Conclusions

This study revealed the high expression of the SARS-CoV-2 receptors, \textit{ACE2} and \textit{TMPRSS2}, at resection margins of lung cancer survivors and its possible relationship with the higher susceptibility of these patients to COVID-19. Clinical data revealed that lung cancer patients, including long-term survivors, diagnosed with COVID-9 infection may have worse outcomes and should be carefully considered.

Abbreviations

COVID-19: Coronavirus disease 2019

SARS-COV-2: Severe acute respiratory syndrome coronavirus 2

ACE2: Angiotensin-converting enzyme 2

TMPRSS2: Transmembrane protease serine 2

IQR: Interquartile range

Declarations

Ethics approval and consent to participate

This study was approved by the Medical Ethical Committee of Wuhan Huoshenshan Hospital (HSSL011), and the Ethical Committee of Nanjing Medical University (2020-511). Written informed consent was obtained from each patient.

Consent for publication

Written informed consent for publication was obtained from all participants.

Availability of data and materials

Software and resources used for the analyses are described in supplementary file.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by National Natural Science Foundation of China (NSFC 81972188, 81572893, 81972358, 81959113); and the Medical Important Talents (ZDRCA2016024). the Key Research & Development Program of Jiangsu Province (BE2017733)
Authors’ Contributions

QW, XX, ZZ, and RG had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. QW, LL, TQ, and LW contributed equally. Concept and design: QW, XX, ZZ, and RG. Data collection: XX, QW, TQ, and ZZ. Data analysis and interpretation: LL, LW, KL, ZW, MZ, BH, WW, MW, and RD. Drafting of the manuscript: QW, LL, TQ, and LW. All authors approved the final manuscript.

Availability of supporting data

Not applicable.

Acknowledgements

Not applicable.

Authors’ information

Qianqian Wang, Liangyu Li, Lingxiang Wu, and Tianyu Qu contributed equally to this work.

References

1. Dai MY, Liu DB, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020;10(6):783-791.

2. Epidemiology Working Group for Ncip Epidemic Response CCfDC, Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145-151.

3. Li WH, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-454.

4. Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2. J Virol. 2010;84(24):12658-12664.

5. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-+.

6. Hirano T, Murakami M. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. Immunity. 2020;52(5):731-733.

7. Lukassen S, Chua RL, Trefzer T, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020;39(10):e105114.

8. Laughney AM, Hu J, Campbell NR, et al. Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nat Med. 2020;26(2):259-269.
## Tables

### Table 1. Characteristics of patients with COVID-19

| Characteristic                  | All patients (n=65) | Lung cancer (n=13) | Non-lung cancer (n=52) | P value |
|--------------------------------|---------------------|--------------------|------------------------|---------|
| **Age, years**                  | 66(56-72)           | 65(63-72)          | 66(56-72)              | 0.761   |
| **Sex**                         |                     |                    |                        |         |
| Male                            | 48(73.8%)           | 10(76.9%)          | 38(73.1%)              | 0.779   |
| Female                          | 17(26.2%)           | 3(23.1%)           | 14(26.9%)              |         |
| **Comorbidities**               |                     |                    |                        |         |
| Any                             | 38(58.5%)           | 8(61.5%)           | 30(57.7%)              | 0.803   |
| Hypertension                    | 22(33.8%)           | 4(30.8%)           | 18(34.6%)              | 0.795   |
| Diabetes                        | 17(26.2%)           | 4(30.8%)           | 13(25.0%)              | 0.674   |
| Chronic obstructive pulmonary disease | 3(4.6%)          | 1(7.7%)           | 2(3.8%)                | 0.557   |
| Coronary heart disease          | 3(4.6%)             | 1(7.7%)           | 2(3.8%)                | 0.557   |
| Cerebrovascular disease         | 5(7.7%)             | 1(7.7%)           | 4(7.7%)                | 1.000   |
| Chronic liver disease           | 4(6.2%)             | 3(23.1%)          | 1(1.9%)                | 0.005   |
| **Symptoms and signs**          |                     |                    |                        |         |
| Fever                           | 50(76.9%)           | 9(69.2%)           | 41(78.8%)              | 0.465   |
| Chill                           | 13(20.0%)           | 2(15.4%)           | 11(21.2%)              | 0.644   |
| Chest pain                      | 1(1.5%)             | 0(0.0%)            | 1(1.9%)                | 0.617   |
| Cough                           | 41(63.1%)           | 8(61.5%)           | 33(63.4%)              | 0.257   |
| Fatigue                         | 30(46.2%)           | 4(30.8%)           | 26(50.0%)              | 0.217   |
| Shortness of breath             | 26(40.0%)           | 5(38.5%)           | 21(40.4%)              | 0.126   |
| Chest tightness                 | 7(10.8%)            | 3(23.1%)           | 4(7.7%)                | 0.112   |
| Expectoration                   | 10(15.4%)           | 3(23.1%)           | 7(13.5%)               | 0.394   |
| Dyspnoea                        | 3(4.6%)             | 2(15.4%)           | 1(1.9%)                |         |
| Diarrhea                        | 3(4.6%)             | 1(7.7%)           | 2(3.8%)                | 0.557   |
| Headache                        | 3(4.6%)             | 0(0.0%)           | 3(5.8%)                | 0.379   |
| Myalgia                         | 12(18.5%)           | 3(23.1%)          | 9(17.3%)              | 0.634   |
| Nausea                          | 1(1.5%)             | 0(0.0%)           | 1(1.9%)                | 0.617   |
| Vomiting                        | 2(3.1%)             | 0(0.0%)           | 2(3.8%)                | 0.476   |

---

### Table 2. Outcome of lung cancer patients and general population
| Characteristic                                      | All (n=65) | Lung cancer (n=13) | Non-lung cancer (n=52) | P value |
|----------------------------------------------------|------------|--------------------|------------------------|---------|
| Hospital stay (days)                               | 11.0(8.0-18.0) | 13.0(11.0-18.0) | 10.0(7.0-17.3) | 0.178   |
| **Most critical type during hospitalization**       |            |                    |                        | 0.064   |
| Mild / Moderate                                    | 29(44.6%)  | 3(23.1%)           | 27(51.9%)              |         |
| Severe / Critical                                  | 35(53.8%)  | 10(76.9%)          | 25(48.1%)              |         |
| **Time from symptoms to hospitalization (days)**   | 19.0(10.0-35.0) | 10.5(10.0-17.5) | 30.0(14.0-35.0) | 0.016   |
| **Clinical symptoms remission time (days)**        | 9.0(6.0-15.0) | 12.0(11.0-18.0) | 8.0(5.8-14.0) | 0.020   |
| Admission to intensive care unit                   |            |                    |                        | 0.433   |
| Yes                                                | 4(6.2%)    | 2(15.4%)           | 2(3.8%)                |         |
| No                                                 | 61(93.8%)  | 11(84.6%)          | 50(96.2%)              |         |
| **ICU stay (days)**                                | 16.5(13.5-21.5) | 13.5(11.3-18.0) | 23.5(19.3-27.8) |         |
| **Clinical outcomes**                              |            |                    |                        | 0.046   |
| Discharge from hospital                            | 64(98.5%)  | 12(92.3%)          | 52(100.0%)             |         |
| Death                                              | 1(1.5%)    | 1(7.7%)            | 0(0.0%)                |         |
| **Time from diagnosis to death (days)**            | 18.0(18.0-18.0) | 18.0(18.0-18.0) | --                     | --      |